Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer types. As per cancer.gov calculations, in 2024, around 234,580 new cases are likely to occur in the United States population. Moreover, 125,070 deaths are predicted in 2024. Hence, leading healthcare companies like AstraZeneca, Merck and Daiichi Sankyo along with research institutions are meticulously working to develop effective drugs for the treatment of the condition. This has led to a significant number of drugs currently in the development pipeline.
The Non-Small Cell Lung Cancer (NSCLC) Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into non-small cell lung cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for non-small cell lung cancer. The non-small cell lung cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The non-small cell lung cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with non-small cell lung cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to non-small cell lung cancer. Moreover, non-small cell lung cancer (NSCLC) collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Non-small cell lung cancer (NSCLC) is the most commonly occurring lung cancer type and can be further categorized into squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. A variety of drugs are used in non-small cell lung cancer (NSCLC) treatment, depending on the stage of the cancer, specific genetic mutations, and the overall health of the patient. These drugs can be categorized into several main classes such as chemotherapy, targeted therapy, and immunotherapy, among others. Chemotherapy includes platinum-based drugs, and antimetabolites while targeted therapy constitutes EGFR inhibitors, ALK inhibitors and ROS1 inhibitors. PD-1 and PD-L1 inhibitors are also common drug classes within immunotherapy drugs.
Common symptoms of non-small cell lung cancer (NSCLC) include persistent cough, chest pain, shortness of breath and fatigue. Smoking is one of the leading causes of the condition. Therefore, the increasing prevalence of smoking in the global population fuels the non-small cell lung cancer (NSCLC) market growth.
The non-small cell lung cancer (NSCLC) pipeline report covers the pathophysiology and epidemiology, developing treatment, and the progress and future aspects of ongoing clinical trials in detail.
This section of the report covers the analysis of non-small cell lung cancer (NSCLC) drugs based on various segmentations such as:
By Phase
EMR’s non-small cell lung cancer (NSCLC) cancer therapeutic assessment report covers 50+ drug analysis based on phase.
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analysis based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes in depth analysis of each drug across these phases. According to EMR analysis, phase II trials cover a major share of the total non-small cell lung cancer (NSCLC) clinical trials conducted, with approximately 3,000 plus drugs in the pipeline.
The route of administration categories covered under the non-small cell lung cancer (NSCLC) pipeline landscape include oral, parenteral, and others. The report provides a comparative analysis of the route of administration for each drug in various phases of clinical trials. According to EMR analysis, the parenteral route holds a significant market share based on the route of administration.
The EMR non-small cell lung cancer (NSCLC) drug pipeline report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in pancreatic cancer clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs. It covers include product description, trial ID, study type, drug class, mode of administration, and recruitment status of non-small cell lung cancer (NSCLC) drug candidates.
Sasanlimab is a PD-1 antagonist monoclonal antibody, designed to be used in combination with a different targeted therapy in each set of the study. Sponsored by Pfizer, Sasanlimab is part of Landscape 1011 clinical research study for individuals with stage 3b or 4 NSCLC. Phase 1b of the sub-study will emphasize on analyzing the safety while phase 2 will focus on evaluating anti-tumor activity in combination.
Designed to treat metastatic or unresectable non-small cell lung cancer (NSCLC), Daiichi Sankyo’s HER3-DXd is being evaluated for its efficacy and antitumor activity. The Open-Label phase 1 study is divided into two parts, including dose expansion and dose escalation. It will be assessed on individuals with advanced NSCLC, having KRAS-G12C mutation.
This interventional study by AstraZeneca evaluates neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus standard of care chemotherapy alone. Currently, under phase III, it is investigating the treatment in patients with resectable EGFRm non-small cell lung cancer.
As a part of KEYMAKER-U01 Substudy 1, a phase 2 umbrella study sponsored by Merck Sharp & Dohme LLC, pembrolizumab (MK-3475) PLUS chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, or MK-0482 is being evaluated for treating advanced non-small cell lung cancer.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Non-Small Cell Lung Cancer (NSCLC) Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for non-small cell lung cancer (NSCLC). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into non-small cell lung cancer (NSCLC) collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Treatment Type |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share